Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Publisher: La Merie Publishing
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0027
Release Date: May of 2018

4,450.00 €
(Discount: 33.33%)
2,966.67 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.

This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

The original reports were published in January and May 2018, respectively:

and

Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product page.

 


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top